Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Virus Diseases 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors That Overexpress HER2 (HER2 Positive) 1Prostatic Neoplasms 1Liver Cirrhosis 1Hepatitis, Viral, Human 1Hepatitis C 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 4Pemetrexed 3Paclitaxel 3Fulvestrant 2FANG vaccine 2Drug Therapy 2Carboplatin 2tucatinib 1trastuzumab deruxtecan 1seribantumab 1selinexor 1osimertinib 1gedatolisib 1dactolisib 1cobimetinib 1cemiplimab 1atezolizumab 1Watchful Waiting 1Trastuzumab 1Transurethral Resection of Prostate 1Trabectedin 1Therapeutics 1Sutures 1Radiation 1Quality of Life 1Pregnancy Tests 1Patient Reported Outcome Measures 1Oxaliplatin 1OSI 930 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Neoplasms × Immunoglobulin G × Clear all
NCT04424641 2023-07-25

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Genmab

Phase 1/2 Terminated
48 enrolled 20 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Prostatic Neoplasms, Uterine Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡